A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Purpose
The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of dupilumab in participants with moderately to severely active Ulcerative Colitis (UC) with an eosinophilic phenotype. Screening period: 2 to up to 4 weeks Treatment period: 52-week investigational medicinal product (IMP) intervention (dupilumab or matching placebo) from Week 0 to Week 52 Open-label arm (optional): administration of open-label dupilumab therapy for study participants who qualify. Follow-up period: 12 weeks The maximum duration of study per participant is up to 68 weeks.
Condition
- Colitis Ulcerative
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants must be ≥18 years of age at the time of signing the informed consent. - Evidence of biomarker enrichment at time of screening. - Moderately to severely active UC, defined as a baseline modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopic subscore assigned during the concurrent local and central reading of the video endoscopy. - Has a screening endoscopy with ≥2 endoscopic subscore in the Mayo score component assessment as determined by concurrent local and central reading of the video endoscopy. - Has a baseline rectal bleeding subscore of ≥1 and baseline a stool frequency score of ≥1 as determined by the Mayo score component assessment. - Participants with inadequate response/non-response, loss of response, or are intolerant of standard biologic therapy for their UC AND/OR Inadequate or non-responders, have shown loss of response, or are intolerant to at least 1 of the following treatments: oral corticosteroids (≤20 mg/day), 5-aminosalicylic acid (ASA) compounds, immunomodulators, small molecules.
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply: - Severe extensive colitis as evidenced by: - Current hospitalization - Likely to require surgery for the treatment of UC within 12 weeks of Screening Visit - UC limited to the rectum only or to <20 cm of the colon as determined by central reading. - Presence of an ileal pouch, ostomy, stoma or fistula or history of a fistula. - Require, or required within the 2 months before screening, surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage, or other conditions possibly confounding the evaluation of benefit from study agent treatment. - Has a prior medical history of eosinophilic colitis. - Participants with abdominal abscess, fulminant disease, or toxic megacolon. - Participants with intestinal failure or short bowel syndrome. - Presence of symptomatic colonic or small bowel obstruction, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy). - History of extensive colonic resection (eg, less than 30 cm of colon remaining) that would prevent adequate evaluation of the effect of study agent on clinical disease activity. - History of colonic mucosal dysplasia or presence of adenomatous colonic polyps not removed OR presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during colonoscopy at screening visit. - If the participant has extensive colitis for ≥8 years or disease limited to left side of colon (ie, distal to splenic flexure) for >10 years, regardless of age, a colonoscopy within 1 year of the screening visit is required to survey for dysplasia. Participants with dysplasia or cancer identified on biopsies will be excluded. - Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease or clinical findings suggestive of Crohn's disease. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Dupilumab |
Initial loading dose followed by regular administration for the duration of the treatment period. |
|
Placebo Comparator Placebo |
Initial loading dose followed by regular administration for the duration of the treatment period. |
|
Other Open-label arm (optional) |
Regular administration of open label dupilumab |
|
Recruiting Locations
Apple Valley, California 92307
Beverly Hills, California 90211
Camarillo, California 93012
Palm Springs, California 92262
Thousand Oaks, California 91360
Homestead, Florida 33033
Miami Lakes, Florida 33016
Naples, Florida 34102
New Port Richey, Florida 34653
Orange Park, Florida 32073
Pembroke Pines, Florida 33025
Tampa, Florida 33609
Roswell, Georgia 30076
East Orange, New Jersey 07018
Jackson Heights, New York 11372
Massapequa, New York 11758
Charlotte, North Carolina 28287
Pittsburgh, Pennsylvania 15213
Decatur, Texas 76234
Katy, Texas 77494
Sherman, Texas 75092
Southlake, Texas 76092
Tyler, Texas 75701
Victoria, Texas 77904
Bellevue, Washington 98004
Tacoma, Washington 98405
San Juan, Puerto Rico 00936
More Details
- NCT ID
- NCT05731128
- Status
- Recruiting
- Sponsor
- Sanofi
Study Contact
Trial Transparency email recommended (Toll free number for US & Canada)800-633-1610
contact-us@sanofi.com